Efficacy Study of IL-21 to Treat Metastatic Melanoma
NCT00336986
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Malignant Melanoma
Interventions
DRUG:
recombinant interleukin-21
Sponsor
Novo Nordisk A/S